Cargando…

Proton pump inhibitor use and risk of hip fracture in patients with type 2 diabetes

Type 2 diabetes mellitus (T2DM) is associated with a high rate of comorbidity, including osteoporosis and peptic ulcers. Proton pump inhibitors (PPIs) are a group of acid-suppressing drugs commonly used for treating peptic ulcers. However, observational studies have reported an association between P...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chou, Ya-Shuan, Jiang, He-Jiun, Chen, Chung-Hwan, Ho, Pei-Shan, Lee, Tien-Ching
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7443131/ https://www.ncbi.nlm.nih.gov/pubmed/32826941 http://dx.doi.org/10.1038/s41598-020-70712-9

Ejemplares similares

Impact of type 2 diabetes on postoperative outcome after hip fracture: nationwide population-based study in Taiwan
por: Lee, Tien-Ching, et al.
Publicado: (2020)

Proton pump inhibitor use is associated with hip fracture development: a nationwide population-based cohort study
por: Min, Yang Won, et al.
Publicado: (2020)

Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study
por: Pouwels, S., et al.
Publicado: (2010)

Proton-Pump Inhibitors and Fragility Fractures in Vulnerable Older Patients
por: Zirk-Sadowski, Jan, et al.
Publicado: (2017)

Proton Pumps: Molecular Mechanisms, Inhibitors and Activators of Proton Pumping
por: Siletsky, Sergey A.
Publicado: (2023)

Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study
por: Khalili, Hamed, et al.
Publicado: (2012)

Proton Pump Inhibitors and the Risk of Early Aseptic Loosening in Hip and Knee Arthroplasty
por: Tamimi, Iskandar, et al.
Publicado: (2022)

The Application of High-Dose Proton Pump Inhibitor Induction Treatment before Dual Therapy for Helicobacter pylori Eradication: An Open-Label Random Trial
por: Chen, Li-Wei, et al.
Publicado: (2021)

Higher dose but not low dose proton pump inhibitors are associated with increased risk of subsequent hip fractures after first hip fracture: A nationwide observational cohort study
por: Brozek, Wolfgang, et al.
Publicado: (2019)

Should we routinely prescribe proton pump inhibitors peri-operatively in elderly patients with hip fractures? A review of the literature
por: Chuene, Mabua A., et al.
Publicado: (2021)

Proton Pump Inhibitors and Gastritis
por: Suzuki, Masayuki, et al.
Publicado: (2008)

Proton pump inhibitors and gastroenteritis
por: Hassing, Robert-Jan, et al.
Publicado: (2016)

Deprescribing proton pump inhibitors
por: Teh, Kim Jun Kevin, et al.
Publicado: (2023)

Proton Pump Inhibitors and Fractures in Adults: A Critical Appraisal and Review of the Literature
por: Briganti, Silvia Irina, et al.
Publicado: (2021)

The effect of proton pump inhibitors on glycaemic control in diabetic patients
por: Rajput, Muhammad Ali, et al.
Publicado: (2020)

The Association between Proton Pump Inhibitors and Myocardial Infarction: What Do Food and Drug Administration Data Tell Us?
por: Tan, Jiun Ming, et al.
Publicado: (2019)

Pharmacokinetics and Pharmacodynamics of the Proton Pump Inhibitors
por: Shin, Jai Moo, et al.
Publicado: (2013)

Proton pump inhibitors and hypomagnesemia monitoring
por: Lemon, Thomas I
Publicado: (2013)

Use and overuse of proton pump inhibitors
por: Staiano, Annamaria, et al.
Publicado: (2015)

Symptomatic hypomagnesemia and proton pump inhibitors
por: Tin, Sim Sai, et al.
Publicado: (2014)

Combination Use of First-Line Afatinib and Proton-Pump Inhibitors Reduces Overall Survival Among Patients with EGFFR Mutant Lung Cancer
por: Ho, Meng-Chin, et al.
Publicado: (2022)

Proton-pump Inhibitor Use and Fracture Risk: An Updated Systematic Review and Meta-analysis
por: Nassar, Yousef, et al.
Publicado: (2018)

Proton Pump Inhibitors and Fracture Risk: A Review of Current Evidence and Mechanisms Involved
por: Thong, Benjamin Ka Seng, et al.
Publicado: (2019)

Diabetic Nephropathy and Proton Pump Inhibitors – Pilot Case-Control Study
por: Raj, Jeffrey Pradeep, et al.
Publicado: (2022)

Risk of Pyogenic Liver Abscess in Proton Pump Inhibitor Users: New Inventory of Proton Pump Inhibitor Induced Complications?
por: Bang, Ki Bae
Publicado: (2021)

Comparison of the Efficacy of Polaprezinc Plus Proton Pump Inhibitor and Rebamipide Plus Proton Pump Inhibitor Treatments for Endoscopic Submucosal Dissection-induced Ulcers
por: Jung, Da Hyun, et al.
Publicado: (2021)

Management of laryngopharyngeal reflux with proton pump inhibitors
por: Reimer, Christina, et al.
Publicado: (2008)

Proton Pump Inhibitor Induced Depigmentation in Vitiligo
por: Holla, Anantha Prasad, et al.
Publicado: (2011)

Proton pump inhibitor-induced hypomagnesemic hypoparathyroidism
por: Swaminathan, Krishnan
Publicado: (2015)

Proton pump inhibitors: A balanced view
por: Ramakrishna, B.S.
Publicado: (2015)

Proton Pump Inhibitors: The Culprit for Barrett’s Esophagus?
por: Alsalahi, Omran, et al.
Publicado: (2015)

Proton pump inhibitors affect the gut microbiome
por: Imhann, Floris, et al.
Publicado: (2016)

Is hypomagnesemia associated with using proton pump inhibitors?
por: Yi, Joo-Hark, et al.
Publicado: (2016)

Proton Pump Inhibitor-associated Mucosal Change
por: Kato, Mototsugu, et al.
Publicado: (2017)

Proton pump inhibitors induce hemolytic anemia
por: Al-Nasser, Asayil Nasser, et al.
Publicado: (2019)

When is proton pump inhibitor use appropriate?
por: Yadlapati, Rena, et al.
Publicado: (2017)

Use of proton pump inhibitors in general practice
por: Tosetti, Cesare, et al.
Publicado: (2017)

Effect of Proton Pump Inhibitors on Colorectal Cancer
por: Sasaki, Takamitsu, et al.
Publicado: (2020)

Problems Associated with Deprescribing of Proton Pump Inhibitors
por: Helgadottir, Holmfridur, et al.
Publicado: (2019)

Proton pump inhibitors in the COVID-19 pandemic()
por: Sebastián Domingo, Juan J.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_k158gpqp2a96vcch5bnmdje6hu